Ortho, Diazyme Assays For Diabetes, Cardiac, And Renal Diseases
In collaboration with Diazyme Laboratories, Ortho Clinical Diagnostics has launched glycated serum protein, lipoprotein (a), and cystatin C assays for use in the detection of diabetes, cardiac, and renal diseases on Ortho's Vitros 5600 Integrated System and Vitros 4600 Chemistry System.
The GSP assay expands Ortho's diabetes menu offering; lipoprotein (a) expands on its offering of diagnostic cardiac markers for patients who may have a genetic risk factor for premature cardiovascular disease; and the cystatin C assay tests for a key marker that enables early diagnosis of chronic kidney disease and complements serum creatinine testing, the firm said.
Ortho said that it is providing the assays to customers as part of its Microtip Partnership Assay program, which enables it to validate and offer high value, esoteric testing in step with the evolving needs of today's labs.
Ortho noted that the assays will initially be available in the US, Europe, Africa, and the Middle East.